Skip to main content

Table 3 Changes (%) in mean and maximum BOLD activities in 3 Brodmann areas (BA) during the motor task at session 1 (baseline), 2 (6 weeks), and 3 (12 weeks)

From: Cortical activation changes and improved motor function in stroke patients after focal spasticity therapy– an interventional study applying repeated fMRI

BA4a
  BOLD mean BOLD max
Pt # L1/L2/L3 R1/R2/R3 (L-R)/R % L1/L2/L3 R1/R2/R3 (L-R)/R %
1 2.90/2.02/1.86 3.19/0.96/0.95 −9/11/10 19.5/10.1/18.9 22.1/5.52/13.7 −12/84/37
2 2.31/3.52/3.68 2.86/5.58/3.80 −19/-36/-3 10.9/28.4/31.7 16.5/33.5/17.2 −34/-15/85
3 2.24/1.43/3.3 2.67/1.36/2.91 −16/5/13 17.8/10.9/19.7 19.1/8.20/15.0 −7/33/31
4 1.20/2.71/2.18 1.59/2.50/1.82 −25/8/20 8.79/26.8/15.4 13.8/14.9/11.9 −36/80/30
5 2.76/2.64/2.58 1.96/3.38/2.38 41/11/8 22.4/19.8/17.0 18.5/13.7/9.64 21/45/76
6 3.62/0.92/0.71 4.69/1.05/1.28 −23/-12/-45 33.1/3.52/4.35 32.0/7.04/15.1 4/-50/-71
Mean 2.51/2.21/2.39 2.83/2.29/2.19 −8/14/15 18.8/16.6/17.8 20.3/13.8/13.8 −11/29/31
Healthy subjects; mean 1.16/1.05 0.66/0.49* 79/130 10.6/8.0 5.70/3.66 108/160
p values 0.011/0.014 0.001/0.001 0.002/0.004 0.034/ns 0.001/0.001 0.003/0.001
BA4p
  BOLD mean BOLD max
Pt # L1/L2/L3 R1/R2/R3 (L-R)/R % L1/L2/L3 R1/R2/R3 (L-R)/R %
1 2.37/1.50/1.55 2.42/0.76/0.83 −2/98/87 19.5/10.1/18.9 22.1/4.53/13.7 −12/123/37
2 1.14/2.75/2.50 1.88/3.44/2.77 −39/-20/-10 8.11/28.4/31.7 12.1/22.8/17.2 −33/25/85
3 1.40/0.98/2.65 1.16/0.73/1.44 21/34/84 10.7/7.89/18.1 14.0/5.18/10.8 −24/52/67
4 0.99/1.41/1.26 1.39/1.31/1.30 −29/8/-3 8.79/16.2/6.91 13.8/14.0/11.9 −36/16/-42
5 2.27/2.12/1.45 1.59/1.70/2.18 43/24/-33 18.5/13.9/8.91 18.5/1.1/9.22 0/15/-3
6 2.96/0.86/0.61 2.96/0.70/0.67 0/22/-9 33.1/2.96/4.35 25.6/7.04/5.38 29/-58/-19
Mean 1.86/1.60/1.67 1.90/1.44/1.53 −1/28/19 16.4/13.3/14.8 17.7/10.9/11.4 −13/29/21
Healthy subjects; mean 0.94/0.87 0.51/0.37* 85/57 8.08/6.73 4.16/2.86 122/149
p values 0.045/0.020 0.001/0.001 0.003/0.004 0.045/ns 0.001/0.001 0.002/0.008
BA6       
  BOLD mean BOLD max
Pt # L1/L2/L3 R1/R2/R3 (L-R)/R % L1/L2/L3 R1/R2/R3 (L-R)/R %
1 2.81/1.96/1.71 3.10/0.94/0.67 −9/108/155 36.4/13.0/18.7 34.7/13.0/3.56 5/0/430
2 2.59/3.93/3.89 2.64/6.15/4.11 −1/-36/-5 10.9/32.8/33.2 16.5/39.5/28.3 −34/-17/17
3 3.08/1.78/3.81 2.71/1.50/3.59 14/0/619 18.3/13.8/22.7 19.1/9.60/20.4 −4/44/11
4 1.51/1.26/2.62 1.30/2.28/1.98 16/-40/33 15.6/26.8/16.7 8.50/13.6/11.9 84/96/41
5 2.52/3.09/4.72 1.53/2.25/3.64 65/37/30 31.9/24.1/39.0 17.7/14.8/25.1 80/63/55
6 5.09/1.23/0.88 4.10/1.06/1.16 24/15/-24 27.0/13.9/5.99 32.0/10.3/15.1 −16/35/-60
Mean 2.93/2.21/2.94 2.56/2.37/2.52 18/16/32 23.3/20.7/22.7 21.4/16.8/17.4 19/37/82
Healthy subjects; mean 1.09/0.94 0.69/0.56 61/76 12.7/9.62 6.08/4.69 119/116
p values 0.003/0.004 0.001/0.001 0.015/0.034 0.034/0.011 0.003/0.001 0.020/0.015
  1. Values from the 10 healthy subjects studied twice serve as reference; p values refer to between-group differences. *p < 0.05 for session 1 vs. 2 in healthy subjects (p < 0.002 applying Bonferroni correction in bold font).